Shield Therapeutics PLC’s (LON:STX) chief executive Tim Watts caught up with Proactive's Andrew Scott on the back of its 2019 results.
He says that finding a US partner for its iron deficiency drug Accrufer is the top priority for 2020.
Shield already has commercial agreements in Europe and China for the drug, which is known as Feraccru outside the US.